Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Timothy Moran Sells 3,192 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 3,192 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $29.56, for a total value of $94,355.52. Following the completion of the transaction, the insider owned 63,153 shares of the company’s stock, valued at $1,866,802.68. The trade was a 4.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 6.5%

KMTS traded down $1.97 on Thursday, hitting $28.53. 730,866 shares of the company were exchanged, compared to its average volume of 361,929. Kestra Medical Technologies, Ltd. has a 12 month low of $17.34 and a 12 month high of $31.91. The company has a market cap of $1.70 billion, a PE ratio of -10.69 and a beta of 0.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. The stock’s fifty day moving average is $26.86 and its 200-day moving average is $23.93.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The company had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. Equities research analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Kestra Medical Technologies in the third quarter valued at approximately $353,000. Sterling Capital Management LLC increased its holdings in shares of Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock worth $25,000 after acquiring an additional 784 shares during the last quarter. Corient Private Wealth LP increased its holdings in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after acquiring an additional 44,839 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after acquiring an additional 7,844 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after acquiring an additional 5,731 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KMTS. Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating on the stock. Evercore initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 price target for the company. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Finally, Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.00.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.